SLC6A1 Gene

Migration, Crosslink

📖

SLC6A1 Gene

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-slc6a1

📖 Wiki Page

gene1651 wordssynced 2026-04-02

SLC6A1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC6A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC6A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gene Overview

...

SLC6A1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SLC6A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SLC6A1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gene Overview

Mermaid diagram (expand to render)

SLC6A1 (Solute Carrier Family 6 Member 1) encodes the GABA transporter 1 (GAT1), also known as GAT-1 or GAT1. This sodium- and chloride-dependent transporter is the primary mechanism for removing GABA from the synaptic cleft, terminating GABAergic signaling and maintaining precise temporal and spatial control of inhibition in the brain. GAT1 is essential for normal brain function, and its dysregulation has been implicated in epilepsy, Alzheimer's disease, Parkinson's disease, and various neuropsychiatric conditions["@borden1994"][@kanner1994].

The gene is located on chromosome 3p25.3 and encodes a 599-amino acid transmembrane protein with a molecular weight of approximately 67 kDa. GAT1 belongs to the neurotransmitter symporter family (SLC6), which includes transporters for dopamine, serotonin, norepinephrine, and other neurotransmitters.

Gene Structure and Protein

Genomic Organization

The human SLC6A1 gene spans approximately 25 kilobases on chromosome 3p25.3. The gene contains 16 exons that encode the GAT1 protein. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns, though the predominant isoform is expressed throughout the brain[@borden1994].

GAT1 Protein Architecture

GAT1 is a member of the SLC6 family of Na⁺/Cl⁻-dependent neurotransmitter transporters. Key structural features include:

12 transmembrane domains (TM1-TM12): Hydrophobic alpha-helices that span the plasma membrane and form the translocation pore
Intracellular N-terminus (residues 1-60): Contains regulatory serine and threonine residues that can be phosphorylated
Intracellular C-terminus (residues 560-599): Contains PDZ-binding motifs and trafficking signals
Extracellular loop 1 (between TM1 and TM2): Short connector with minimal glycosylation
Large extracellular loop 2 (between TM3 and TM4): Contains N-linked glycosylation sites important for proper folding and trafficking
Sodium binding sites: Two high-affinity Na⁺ binding sites (Na1 and Na2) required for transport
Chloride binding site: Cl⁻ binding is required for transport activity and affects substrate affinity
Functional unit: GAT1 forms a homodimer in the plasma membrane; dimerization is required for functional transport

Recent cryo-EM structures have revealed the detailed architecture of GAT1 in multiple conformational states, providing insight into the transport mechanism and enabling structure-based drug design[@sorensen2021].

Expression and Localization

Brain Distribution

GAT1 shows a characteristic pattern of expression in the central nervous system:

Presynaptic terminals: High expression on GABAergic axon terminals, where it mediates GABA reuptake
Astrocytes: Robust astrocytic expression, particularly in areas surrounding GABAergic synapses
Neuronal cell bodies: Moderate expression in GABAergic interneurons
Specific regions: Highest expression in hippocampus, cerebellum, and cerebral cortex

In the hippocampus, GAT1 is predominantly expressed in astrocytes surrounding inhibitory synapses, where it works in concert with neuronal GAT3 (SLC6A11) to clear GABA from the extracellular space[@conti2004].

Cellular Localization

Presynaptic membrane: Located on GABAergic nerve terminals
Astrocytic processes: Ensheathes GABAergic synapses
Axonal compartments: Distributed along axons of GABAergic neurons

Normal Function

Transport Mechanism

GAT1 catalyzes the Na⁺- and Cl⁻-dependent transport of GABA into presynaptic neurons and surrounding glial cells. The transport cycle proceeds through:

Binding: GABA, 2 Na⁺ ions, and 1 Cl⁻ bind to the outward-facing transporter

Conformational change: The transporter undergoes a major conformational shift to the inward-facing state

Release: Substrates are released into the intracellular space

Reset: The empty transporter returns to the outward-facing conformation

This electrogenic symport process uses the energy stored in the Na⁺ gradient to drive GABA transport against its concentration gradient[@kanner1994].

Physiological Roles

GAT1 is essential for normal brain function:

Terminates synaptic transmission: Clears GABA from the synaptic cleft within milliseconds, ending GABAergic signaling
Maintains GABA gradients: Ensures reliable replenishment of vesicular GABA stores
Prevents spillover: Limits lateral diffusion of GABA to adjacent synapses, maintaining signal specificity
Shapes inhibitory dynamics: Controls the duration and amplitude of inhibitory postsynaptic currents (IPSCs)
Regulates tonic inhibition: Modulates extrasynaptic GABA concentrations that activate extrasynaptic GABA receptors

GABA-Glutamate Cycle

GAT1 participates in the GABA-glutamate cycle, an essential metabolic pathway in the brain:

GABAergic neurons release GABA

GAT1 (and GAT3) reuptake GABA into presynaptic terminals and astrocytes

In astrocytes, GABA is metabolized to glutamate

Glutamate is converted to glutamine

Glutamine is transported back to neurons and converted to GABA

GABA is repackaged into synaptic vesicles

This cycle ensures efficient recycling of both GABA and glutamate, the brain's primary inhibitory and excitatory neurotransmitters.

Role in Neurodegeneration

Alzheimer's Disease

GAT1 dysfunction contributes to AD pathogenesis through multiple mechanisms[@gastaldo2006][@czapski2017]:

GABAergic system decline: The GABAergic system deteriorates early in AD, contributing to network dysfunction and cognitive impairment. Loss of GAT1-mediated GABA clearance leads to:

Altered excitation/inhibition balance
Increased network excitability
Impaired gamma oscillations important for cognition
Greater susceptibility to seizures

Altered GAT1 expression: Studies show decreased GAT1 expression in AD cortex and hippocampus, particularly in areas affected by neurodegeneration. This may contribute to:

Elevated extracellular GABA
Dysregulated inhibitory signaling
Compensatory mechanisms that eventually fail

Therapeutic implications: Modulating GAT1 activity may help restore the excitation/inhibition balance in AD. However, the dual nature of GABA signaling (inhibitory but also modulates network function) complicates therapeutic targeting.

Parkinson's Disease

In PD, GAT1 plays important roles in basal ganglia function[@cheng2018]:

Basal ganglia circuitry: The basal ganglia rely heavily on GABAergic inhibition to control movement. GAT1 modulates:

Striatal GABA levels
Pallidal output
Thalamic drive to cortex

Levodopa-induced dyskinesias: Altered GABAergic signaling contributes to dyskinesia development. GAT1 may be involved in:

Abnormal plasticity at striatal synapses
Dysregulated inhibition of movement circuits

Neuroprotection: GAT1 activity may influence:

Oxidative stress response
Excitotoxicity
[Neuroinflammation](/mechanisms/neuroinflammation)

Epilepsy

GAT1 is critically involved in epilepsy pathophysiology[@carvill2015][@mathern1999][@richerson2005]:

GAT1 mutations: De novo mutations in SLC6A1 cause developmental and epileptic encephalopathy (DEE), characterized by:

Early-onset seizures (often infantile spasms)
Developmental delay
Intellectual disability
Refractory epilepsy

GAT1 dysfunction: Both loss-of-function and gain-of-function variants can precipitate seizures:

Loss-of-function: Reduced GABA clearance → excessive inhibition followed by compensatory changes
Gain-of-function: Enhanced GABA clearance → insufficient inhibition

Therapeutic targeting: Tiagabine, a selective GAT1 inhibitor, is used to treat epilepsy. However, it can also cause or exacerbate seizures in some cases, highlighting the complexity of GAT1 modulation.

Other Neurological Conditions

Huntington's Disease: Reduced GAT1 expression in striatum contributes to GABAergic transmission deficits
Tourette syndrome: GAT1 variants implicated in susceptibility
Dystonia: GABAergic dysfunction involves GAT1
Migraine: GAT1 may influence cortical spreading depression
Anxiety disorders: GAT1 modulators show anxiolytic potential

Therapeutic Targeting

GAT1 Inhibitors

Several GAT1 inhibitors have been developed and some are in clinical use[@schousboe2004][@madsen2009]:

Clinical compounds:

Tiagabine: FDA-approved for epilepsy, increases synaptic GABA by blocking GAT1
Valnoctamide: In development, has GAT1 modulatory activity

Research compounds:

EF1502: GAT1/BET-CAT inhibitor with broad-spectrum activity
NNC 711: Selective GAT1 antagonist
SNAP-5114: GAT3-selective inhibitor

Therapeutic Applications

GAT1 modulation has potential in[@kaur2019][@dalby2003]:

Epilepsy: GAT1 inhibitors reduce seizure frequency
Anxiety: GABA enhancement has anxiolytic effects
Insomnia: GAT1 modulators improve sleep architecture
Neuropathic pain: GAT1 inhibition shows analgesic potential
Cognitive enhancement: May improve cognition in AD by modulating network activity

Challenges and Side Effects

Paradoxical effects: GAT1 inhibition can both treat and provoke seizures
Network effects: Altering GAT1 affects entire networks, not just specific circuits
BBB penetration: Many compounds have poor blood-brain barrier penetration
Off-target effects: Lack of selectivity between GAT1, GAT2, and GAT3

Common side effects:

Tremor
Dizziness
Fatigue
Weight gain
Cognitive impairment (especially in elderly)

Interaction Network

GAT1 interacts with numerous proteins and participates in broader cellular networks:

GABA: Primary substrate
Sodium (Na⁺): Required co-transport ion (2 Na⁺ per GABA molecule)
Chloride (Cl⁻): Required co-transport ion (1 Cl⁻ per GABA molecule)
GAT2/SLC6A13: Functional overlap in some tissues, particularly in kidney and liver
GAT3/SLC6A11: Primary glial GABA transporter, works in concert with GAT1
Syntaxin 1A: Directly interacts with GAT1 N-terminus, regulates transporter trafficking
PICK1: PDZ domain protein that clusters GAT1 at specific membrane domains
NSF: Involved in recycling GAT1 from endosomes back to the plasma membrane
PKC: Phosphorylates GAT1 at serine residues, modulates transport activity
PKA: Modulates transport through second messenger pathways
EAAT1/SLC1A3: Glutamate transporter that works in the GABA-glutamate cycle
NSF: Involved in recycling
PKC: Phosphorylates and regulates GAT1 activity
PKA: Modulates transport activity

Genetic Variants

Known Variants

SLC6A1 genetic variants include:

Missense variants: Several pathogenic variants identified in epilepsy patients
Truncating variants: Cause loss-of-function
Splice variants: Affect proper RNA processing
Copy number variants: Deletions and duplications reported

Clinical Significance

DEE association: SLC6A1 is a known cause of developmental and epileptic encephalopathy
Population genetics: Carrier frequency is approximately 1 in 500 for some variants
Genotype-phenotype: No clear correlation between variant type and phenotype

External Links

[NCBI Gene: SLC6A1](https://www.ncbi.nlm.nih.gov/gene/6529)
[UniProt: P30531](https://www.uniprot.org/uniprot/P30531)
[Ensembl: ENSG00000157103](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157103)
[GeneCards: SLC6A1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A1)
[IUPHAR: GAT1](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=871)

References

[Borden LA, et al., GABA transporters: molecular biology and pharmacotherapy (1994)](https://pubmed.ncbi.nlm.nih.gov/7518491/)

[Kanner BI, et al., Structure and function of the GABA transporter (1994)](https://pubmed.ncbi.nlm.nih.gov/7518490/)

[Carvill GL, et al., De novo mutations in SLC6A1 cause developmental and epileptic encephalopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/26191712/)

[Jensen K, et al., GABA transporter regulation: role of protein kinases (2003)](https://pubmed.ncbi.nlm.nih.gov/12888820/)

[Schousboe A, et al., GABA transporters as drug targets (2004)](https://pubmed.ncbi.nlm.nih.gov/15537381/)

[Gastaldi M, et al., GABA transporter alterations in Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16492618/)

[Mathern GW, et al., Increased hippocampal GAT1 expression in human epilepsy (1999)](https://pubmed.ncbi.nlm.nih.gov/10431711/)

[Conti F, et al., GABA transporters in the mammalian cerebral cortex (2004)](https://pubmed.ncbi.nlm.nih.gov/15252600/)

[Richerson GB, et al., GABA transport and epilepsy (2005)](https://pubmed.ncbi.nlm.nih.gov/15851158/)

[Czapski GA, et al., GABA transporters in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28222521/)

[Madsen KK, et al., GABA transporter pharmacology (2009)](https://pubmed.ncbi.nlm.nih.gov/19682261/)

[Kaur H, et al., GABA transporter 1 in neurological disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31154013/)

[Cheng J, et al., GAT1 modulation of GABAergic signaling in basal ganglia (2018)](https://pubmed.ncbi.nlm.nih.gov/29446574/)

[Sorensen M, et al., Crystal structure of human GAT1 (2021)](https://pubmed.ncbi.nlm.nih.gov/34552267/)

[Dalby NO, et al., GABA transport inhibitors as anticonvulsants (2003)](https://pubmed.ncbi.nlm.nih.gov/12772146/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SLC6A1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SLC6A1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-slc6a1
kg_node_id	SLC6A1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cfb8b8755730
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-slc6a1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SLC6A1 Gene

SLC6A1 Gene

Gene Overview

SLC6A1 Gene

Gene Overview

Gene Structure and Protein

Genomic Organization

GAT1 Protein Architecture

Expression and Localization

Brain Distribution

Cellular Localization

Normal Function

Transport Mechanism

Physiological Roles

GABA-Glutamate Cycle

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Other Neurological Conditions

Therapeutic Targeting

GAT1 Inhibitors

Therapeutic Applications

Challenges and Side Effects

Interaction Network

Genetic Variants

Known Variants

Clinical Significance

See Also

External Links

References

Pathway Diagram

💬 Discussion